Nasdaq · CIK 0002046386 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Medline Inc.
MDLN chart by TradingView
PRICE HISTORY
LIVE · NASDAQMDLN chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $28.4B
- EBITDA
- $3.2B
- FREE CASH FLOW
- $1.3B
- EPS
- $1.43
- GROSS MARGIN
- 26.44%
- ROIC
- 5.43%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 4 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
32.6x
⤢
P / SALES (TTM)
1.2x
⤢
P / BOOK
2.9x
-4%2.9x3.0x
⤢
EV / EBITDA (TTM)
15.2x
⤢
EV / REVENUE (TTM)
1.5x
⤢
FCF YIELD (TTM)
4.75%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$7.7B
+16%⤢
EBITDA (DERIVED)
$0.6B
-30%⤢
NET INCOME
$0.1B
-56%⤢
EPS (DILUTED)
$0.16
-44%⤢
REVENUE GROWTH YOY
—
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
7.86%
-0.9pp1.26%8.79%
⤢
RETURN ON CAPITAL
4.70%
⤢
RETURN ON EQUITY (TTM)
8.87%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN28.82%
OPERATING MARGIN5.14%
NET MARGIN1.81%
FCF MARGIN7.86%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.6B
+3%⤢
STOCK-BASED COMP
$0.0B
+53%⤢
CAPITAL EXPENDITURE
$0.1B
+13%⤢
SHARES OUTSTANDING
0.86B
+4%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$2.3B
+4%⤢
TOTAL DEBT
$12.6B
+0%⤢
DEBT / EBITDA (TTM)
4.4x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 108.30%INSIDERS 0.20%OTHER / RETAIL 0.00%518 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Carlyle Group Inc. | 21.32% | 187.1M | $6.59B | -13.1% |
| H&f Corporate Investors X, Ltd. | 9.86% | 86.5M | $3.05B | -13.1% |
| FMR, LLC | 4.17% | 36.6M | $1.29B | +38.7% |
| Capital Research Global Investors | 2.64% | 23.2M | $816.0M | +56.7% |
| Invesco Ltd. | 2.39% | 21.0M | $738.5M | +728.8% |
| Massachusetts Financial Services Co. | 2.27% | 19.9M | $700.7M | +71.9% |
| Blackrock Inc. | 1.93% | 16.9M | $596.2M | +47.0% |
| Egerton Capital (UK) LLP | 1.88% | 16.5M | $580.3M | +277.3% |
| Morgan Stanley | 1.79% | 15.7M | $553.2M | +3.6% |
| Vanguard Capital Management LLC | 1.68% | 14.7M | $518.9M | NEW |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.